Application Page

Page last updated: 24 March 2023 (this page is generated automatically and reflects updates to other content within the website)

Application pages in development

    Enter application number or key word/s e.g. 1401 e.g. advanced biopsy
MSAC Applications
ID/Title
1748 – Review of Tisagenlecleucel for treatment of confirmed relapsed/refractory CD19-positive acute lymphoblastic leukaemia in children and young adults up to 25 years old
1747 – Permanent Medicare Benefits Schedule (MBS) items for COVID-19 nucleic acid testing
1689.1 – Quantification of NT-proBNP in patients with diagnosed pulmonary arterial hypertension for ongoing risk assessment
1686.1 –177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer
1734 – Intravascular lithotripsy for the treatment of moderately or severely calcified peripheral artery disease
1739 – Percutaneous electrical nerve stimulation therapy for chronic neuropathic pain
1741 – Continuous nerve blockade using a catheter technique
1740 – N-Terminal-pro Brain Natriuretic Peptidete (NT-proBNP) to aid in the diagnosis of patients with suspected heart failure in a non-hospital setting
1728 – Etranacogene dezaparvovec for the treatment of Haemophilia B
1744 – 177Lutetium(nca) Octreotate treatment for advanced neuroendocrine and other high somatostatin receptor expressing tumours
1549 – PD-L1 immunohistochemistry testing for access to pembrolizumab in combination with chemotherapy for first line treatment of triple negative breast cancer
1726 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS niraparib
1658.1 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib
1724 – Cardiac technical support services provided by industry employed allied health professionals
1737 – Newborn bloodspot screening for Sickle Cell Disease and Beta Thalassaemia
1736 – Lipoprotein(a) testing as an independent predictor of cardiovascular disease
1732 – Imlifidase as a desensitisation treatment to enable kidney transplant in highly sensitised adult transplant candidates
1727 – Deep brain stimulation for treatment-refractory obsessive compulsive disorder
1725 – Transanal total mesorectal excision for the treatment of rectal cancer and benign disease
1718 – PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for persistent, recurrent, or metastatic cervical cancer, to determine eligibility for pembrolizumab treatment
1723 – Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia
1677.1 – Pharmacy Diabetes Screening Trial
1525.1 – Low dose rate brachytherapy for intermediate and high-risk prostate cancer
1662.1 – The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques
1722 – Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma
1719 – Insertion of a bioabsorbable implant for nasal airway obstruction due to lateral wall insufficiency
1710 – Newborn bloodspot screening for X-linked adrenoleukodystrophy
1716 – Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment
1717 – Extravascular implantable cardioverter defibrillator therapy for patients at risk of ventricular arrhythmia
1714 – National Blood Authority listing for Obizur® (susoctocog alfa) for treatment of bleeding episodes with acquired Haemophilia A
1721 – Small gene panel testing for non-small cell lung carcinoma
1713 – Cardiac MRI in the diagnosis of myocarditis
1712 – Out-of-laboratory sleep studies in the diagnosis and management of sleep disordered breathing in children & adolescents
1408.1 – A prognostic RT-qPCR test for prediction of risk of distant recurrence of breast cancer under endocrine treatment
1709 – Somatic gene testing for the diagnosis of glioma, including glioblastoma
1711 – Review of MBS items for subacromial decompression
1706 – Angiogenic and anti-angiogenic markers for identification and management of preeclampsia
1705 – Structured prenatal risk assessment for preterm preeclampsia
1701 – Deep brain stimulation of the thalamus for the treatment of severe refractory epilepsy
1700 – Totally thoracoscopic exclusion of the left atrial appendage for patients with non-valvular atrial fibrillation
1702 – Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours
1708 – Hepatitis Delta Virus (HDV) RNA PCR testing to determine eligibility for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of HDV
1707 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia
1703 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia
1695 – Procedures for the implantation and refill-exchange of the Port Delivery System with ranibizumab to treat neovascular age-related macular degeneration
1678 – Integrating Pharmacists within Aboriginal Community Controlled Health Services to Improve Chronic Disease Management (IPAC Project)
1698 – Chronic Pain MedsCheck Trial
1699 – National Lung Cancer Screening Program
1679 – Improved medication management for Aboriginal and Torres Strait Islanders Feasibility Study (IMeRSe Feasibility Study)
1614.1 – Magnetic resonance-guided focused ultrasound for the treatment of medically refractory essential tremor
1686 –177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer
1690 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma
1684 – Genetic testing for variants associated with haematological malignancies
1675 – Whole Genome Sequencing for the diagnosis of mitochondrial disease
1683 – MRI of the liver, for the evaluation of hepatic metastases for initial staging or restaging prior to treatment using interventional techniques
1682 – Amendment to MBS Item 63464 – MRI for the detection of breast cancer in asymptomatic high-risk patients
1691 – PromarkerD testing in patients with type 2 diabetes to determine the risk of developing diabetic kidney disease
1689 – Quantification of NT-proBNP in patients with systemic sclerosis, and in patients with diagnosed pulmonary arterial hypertension
1697 – Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia
1685 – Ventral rectopexy for the treatment of rectal prolapse and intussusception
1680 – Genetic testing for childhood hearing impairment
1665 – Radiofrequency echographic multi spectrometry for bone density measurement and determination of osteopenia/osteoporosis
1555.1 – Endoscopic sleeve gastroplasty for the treatment of patients with Class I and II obesity who have failed first line (lifestyle modification) and second line (pharmacotherapy) treatments
1677 – Pharmacy Diabetes Screening Trial
1602.1 – Testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusion status, in patients with locally advanced or metastatic solid tumours, to determine eligibility for larotrectinib
1522.1 – PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma
1676 – Amendments to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma – amend clinical criteria for patients with Transformed Follicular Lymphoma (TFL) and propose inclusion of patients with grade 3B follicular lymphoma (3B FL)
1637 – Expanded Reproductive Carrier Screening of couples for joint carrier status of genes associated with autosomal recessive and X-linked conditions
1674 – Testing for mismatch repair deficiency (dMMR) in endometrial cancer to help determine eligibility for PBS-subsidised dostarlimab
1672 – Procedures for the insertion or removal of a leadless permanent pacemaker for the treatment of bradyarrhythmia
1627 – Point-of-care testing for sexually transmitted infections provided by Aboriginal Medical Services or Aboriginal Community Controlled Heath Services in rural or remote areas
1671 – Targeted carrier testing for severe monogenic conditions
1669 – KRAS G12C variant testing to determine eligibility for PBS-subsidised sotorasib second-line therapy in patients with locally advanced or metastatic non small cell lung cancer
1595.1 – Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to, continuous positive airway pressure therapy
1666 – Exclusion of the left atrial appendage via surgical epicardial clip implantation concomitant to open cardiac surgery for patients with atrial fibrillation
1668 – Whole body magnetic resonance imaging for detection of cancer in individuals with germline pathogenic TP53 variants
1673 – Single operator, single use, peroral cholangiopancreatoscopy for diagnosis of indeterminate biliary strictures and removal of difficult biliary stones
1546.1-Abdominoplasty with repair of rectus diastasis (also known as rectus divarication) following pregnancy
1640 - Transcatheter Aortic Valve Implantation (TAVI) via transfemoral delivery for patients at low risk for surgery
1354.1 – Intravascular ultrasound guided coronary stent insertion
1646 – Whole genome sequencing of antimicrobial-resistant pathogens
1662 – The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques
1661 – Implantation of minimally invasive interspinous decompression spacers for moderate degenerative lumbar spinal stenosis
1657 – Rhenium-188 brachytherapy for non-melanoma skin cancer
1658 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib
1660 - Diagnostic testing for mesenchymal-epithelial transition Exon 14 skipping alterations in non-small cell lung cancer, to determine Pharmaceutical Benefits Scheme eligibility for tepotinib treatment
1656 – Vertebral body tethering for adolescent idiopathic scoliosis
1659 – Catheter-based renal denervation for uncontrolled elevated systolic blood pressure
1664 - Improvements to the National Cervical Screening Program Self-Collection Policy
1663 – Review of Continuous Glucose Monitoring (CGM) products provided through the CGM Initiative
1642 – Programmed Death Ligand 1 testing for access to cemiplimab for the treatment of locally advanced or metastatic non-small cell lung cancer
1652 – Transcatheter aortic valve implantation via transfemoral delivery for patients at intermediate risk for surgery
1647– Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
1374.1 – Subcutaneous implantable cardioverter defibrillator therapy for the prevention of sudden cardiac death
1653 – Amendment to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma - removal of the requirement for patients to be “CD19-positive”
1649 – Modification of the wording of minimally invasive glaucoma surgery (MIGS) existing item number to encompass the use of a microcatheter
1643 - Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule-subsidised aducanumab in patients with early stage Alzheimer Disease
1648 - OncoSil™ for locally advanced unresectable pancreatic cancer
1634 – Comprehensive genomic profiling of non-small cell lung cancer tumour tissue specimens using next generation sequencing assays
1651 – Integrated, closed-system, extracorporeal photopheresis systems for the treatment of chronic graft-versus-host disease
1195.1 - F-18 flurodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer Disease
1631 - Home sleep apnoea test utilizing peripheral arterial tone
1635 - Transcatheter aortic valve implantation via transfemoral delivery using the balloon-expandable valve system for patients at low risk for surgery
1630 - Hypoglossal nerve stimulation using the Genio System for the treatment of moderate to severe obstructive sleep apnoea (OSA) in patients who have failed or are intolerant to continuous positive airway pressure (CPAP)
1624 - 17p deletion testing for access to acalabrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
1610 - Clostridium botulinum type A toxin-haemagglutin complex (Dysport) for the treatment of moderate to severe upper-limb spasticity due to cerebral palsy
1629 – Defensive Antibacterial Coating (DAC) 5ml Kit
1582 - Detection of Aquaporin-4 (AQP4) antibodies in serum of cerebrospinal fluid for diagnosis of Neuromyelitis optica (NMO)
1632 – PSMA PET/CT imaging for informing treatment of patients with prostate cancer
1638 – Proton beam therapy for paediatric and rare cancers
1628 – Alpha-1-Antitrypsin Genotyping
1612 - Prostatic urethral lift procedure for men with benign prostatic hyperplasia
1625 – Dinutuximab beta for high-risk neuroblastoma
1586 - Transurethral water vapour ablation for the treatment of benign prostatic hyperplasia
1622 - Cardiac ablation devices for use in ventricular arrhythmia and supraventricular tachycardia
1623 – Voretigene neparvovec (Luxturna) for the treatment of biallelic RPE-65-mediated Inherited Retinal Dystrophies
1626 – Mentor Textured breast implants and expanders compared with smooth breast implants and expanders on the Prostheses List
1618 – Testing of tumour prostate tissue to detect BRCA1/2 pathogenic gene variants in men with metastatic castration-resistant prostate cancer to help determine eligibility for PBS olaparib
1620 – Magnetic Resonance Image Guided Radiation Therapy
1619 – Testing of blood to detect pathogenic germline BRCA1 or BRCA2 gene variants, in patients with metastatic pancreatic cancer to help determine eligibility for PBS olaparib
1607 – 17p deletion testing for access to acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia
1621 - Amendment to MBS Item 73344 for c-ROS proto-oncogene 1 fluorescence in situ hybridisation testing to identify ROS1, to determine patient eligibility for entrectinib under the Pharmaceutical Benefits Scheme
1617 - BRAF V600 testing to help determine eligibility for PBS access to Braftovi (encorafenib), in patients with metastatic colorectal cancer (Stage IV)
1615 – Transcatheter occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation
1613 – Permanent acute coronary syndrome event detector (insertion, removal or replacement of) for monitoring of the heart's electrical activity
1614 – Magnetic resonance-guided focused ultrasound for the treatment of medically refractory essential tremor
1485.1 - Sentinel Lymph Node Biopsy for intermediate thickness melanoma
1344.2 - Assessment of foot and ankle services by podiatric surgeons (Resubmission)
1420.1 - Extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma
1608 - Amnion membrane (human tissue) for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
1568 - Germline BRCA mutation testing to determine eligibility for talazoparib treatment in patients with locally advanced or metastatic HER2-negative breast cancer (either hormone receptor positive or triple negative)
1606 – Request to amend existing MBS Item No 73341 (Fluorescence in situ hybridisation test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer) to add brigatinib
1584 – Radionuclide Imaging for for the diagnosis of transthyretin amyloid cardiomyopathy
1196.3 - Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression (Resubmission)
1602 - Testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusion status, in patients with locally advanced or metastatic solid tumours, to determine eligibility for larotrectinib
1605 - Transcatheter delivery of a dual-filter cerebral embolic protection system during transcatheter aortic valve implantation
1604 - PIK3CA mutation testing for postmenopausal women or men with advanced breast cancer who have progressed during or following treatment with an aromatase inhibitor
1603 - Transcatheter aortic valve implantation (TAVI) via transfemoral delivery, using the SAPIEN 3 balloon-expandable valve (BEV) system, for patients at intermediate risk for surgery
Sixth Community Pharmacy Agreement (6CPA) Medication Management Review (MMR) Programs
1599 - Genomic testing for the diagnosis of heritable cardiomyopathies
1600 - Genetic testing for heritable kidney disease (other than Alport syndrome)
1598 - Genetic testing for diagnosis of inheritable cardiac rhythm disorders
1595 - Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to, continuous positive airway pressure (CPAP) therapy
1597 - Cryoablation for biopsy-confirmed renal cell carcinoma (RCC) ≤4cm in patients not suitable for partial nephrectomy
1596 - Coronary artery bypass graft surgery with one or more saphenous vein grafts, supported and reinforced by an external mesh support
1585 - Genetic testing for the diagnosis of early-onset or familial neuromuscular disorders
1429.1 - Targeted intraoperative radiotherapy for early-stage breast cancer
1353.1 - Measurement of Calprotectin as a marker of bowel inflammation
1592 - Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
1591 - Review of immunoglobulin use for secondary hypogammaglobulinaemia unrelated to haematological malignancies, or post-haemopoietic stem cell transplant
1590 - Review of immunoglobulin use for multifocal motor neuropathy
Sixth Community Pharmacy Agreement (6CPA) Pharmacy Practice Incentives (PPI) Programs
1593 - Bovine bioinductive collagen implant for repair of rotator cuff tear
1577 - Autologous fat grafting (AFG) by injection, for treatment of burn scars, and treatment of facial defects due to craniofacial abnormalities
1578 - Arthroscopic injection of a bioadhesive hydrogel implant (JointRep™), in conjunction with microfracture, for treatment of osteochondral defects of the knee
1573 - Reproductive carrier screening for fragile X syndrome, spinal muscular atrophy and cystic fibrosis
1589 – Prognostic value of the number of copies of the survival of motor neurone 2 (SMN2) gene for the severity of spinal muscular atrophy to determine eligibility for nusinersen in pre-symptomatic patients (Co-dependent)
1519.1 - Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma
1435.1 - Processing and Cryopreservation of Ovarian Tissue
1342.5 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)
1196.2 - Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression (Resubmission)
1510.1 - Emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with Haemophilia A
1192.3 - Reduction of mitral regurgitation through tissue approximation, using transvenous/transeptal techniques (Resubmission)
1587 - YESCARTA™ (axicabtagene ciloleucel [KTE-C19]) for the treatment of refractory or relapsed CD19-positive lymphoma
1532 - Expansion of genetic testing for myeloproliferative neoplasms under MBS item 73325
1531 - Genetic testing of alpha thalassaemia
1579 - Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with moderate to severe Haemophilia A (congenital Factor VIII deficiency) WITHOUT Factor VIII inhibitors
1567 - Digital breast tomosynthesis
1560 - 17p Deletion Testing by FISH for Access to Ibrutinib in Patients with Previously Untreated Chronic Lymphoid Leukaemia or Small Lymphocytic Lymphoma
1543 - Request to amend Medicare Benefits Schedule (MBS) item 73336 (BRAF mutation test for treatment of metastatic melanoma) to include reference to encorafenib
1570 - PD-L1 (Programmed Death Ligand 1) immunohistochemistry (IHC) testing for access to atezolizumab as first line therapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC)
1574 – Non-Invasive Prenatal Testing (NIPT) for fetal Rhesus D genotype
1569 - Chitosan-based cartilage biomatrix implant (BST-CarGel), in conjunction with the marrow stimulation technique (microfracture), for repair of focal cartilage defects
1575 - Autologous fat grafting (AFG) by injection, for defects arising from breast surgery, cancer treatment/prevention or congenital deformity
1431.1 - HbA1c point of care test for the management of diabetes mellitus
1572 - Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure ≥ 140/90mmHg and ≤ 180/110mmHg
1559 - Endoscopic Mucosal Resection
Please Note: Information will be published for this application when it becomes available
1564 – Review of immunoglobulin use for Chronic Inflammatory Demyelinating Polyneuropathy
1566 - Review of immunoglobulin use for Myasthenia Gravis
1565 - Review of immumnoglobulin use for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation
1580 - Cardiac ablation for atrial fibrillation
1387.2 - Optimizer® Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure (resubmission)
1405.1 - MBS Item for Pulmonary Rehabilitation (Re-submission)
1544 - Genome-wide microarray testing for people with multiple myeloma and chronic lymphocytic leukaemia
1533 - Genome-wide microarray testing for pregnancies with major foetal structual abnormalities detected by ultrasound
1556 - Human tissue (topical) wound treatments – Ulcers and burns (EpiFix and EpiBurn)
1557 - Human tissue (surgical) wound treatments – Laminectomy and tendon repair (AmnioFix, AmnioWrap and AmnioFix Injectable)
1555 - Endoscopic Sleeve Gastroplasty (ESG) for the treatment of patients with Class I and Class II obesity with comorbidities who have failed first-line treatments
1562 – Streamlining Medicare Benefits Schedule Items for Positron Emission Tomography (PET) Project
1541- Micro-bypass glaucoma surgery (MBGS) device implantation as a standalone procedure in patients with open-angle glaucoma (OAG)
1554 - Testing of tumour tissue or blood to detect somatic or germline BRCA1 or BRCA2 gene mutations, in a patient with newly diagnosed, advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy).
1552 - Transcatheter Aortic Valve Implantation (TAVI) via Transfemoral Delivery for Patients at Intermediate Risk for Surgery
1551 - Aspiration therapy via the insertion of a customised percutaneous endoscopic gastrostomy tube into the stomach for weight loss management in obese patients with a BMI ≥ 35
1546 - Abdominoplasty with repair of rectus diastasis (aka rectus divarication) following pregnancy
1486 - Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with advanced or metastatic non-small-cell lung cancer (NSCLC)
1553 - Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors
1542 - Endovascular insertion of flow diversion device (FDD) for the treatment of unruptured intracranial aneurysms (UIAs)
1534 - Heritable mutations associated with familial hypercholesterolaemia - Clinical Utility Card application
1446 - Hepascore test to diagnose and monitor liver fibrosis severity in chronic liver disease
1515 - Endoscopic placement and removal of an intra-gastric balloon (IGB) for the management of overweight and obesity in a high-risk patient
1441 - Inclusion of eye movement de-sensitisation and reprocessing (EMDR) therapy as a separate Focussed Psychological Therapy under Medicare's Better Access to Psychology Scheme
1538 - Tumour testing to detect somatic BRCA1 or BRCA2 gene mutations, in patients with platinum-sensitive, relapsed high-grade serous ovarian cancer (HGSOC), to determine eligibility for PBS olaparib
1540 - Vigilance testing for the assessment of excessive daytime sleepiness
1523 - Transluminal insertion, management, repositioning and removal of an intravascular microaxial blood pump (Impella®), for patients requiring mechanical circulatory support
1516 - Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) to determine eligibility for osimertinib
1492 – Non-invasive prenatal testing (NIPT)
1504 - Heritable mutations which increase risk in colorectal and endometrial cancer
1522 - PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (co-dependent)
1524 - Expanding the BRAF testing MBS item to include patients with resectable Stage III melanoma (co-dependent)
1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)
1518 - Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH)
1520 - PD-L1 (Programmed Death 1 Ligand) immunohistochemistry testing for access to pembrolizumab as second/third-line treatment of patients with recurrent or metastatic, unresectable (advanced) adenocarcinoma of the stomach or GEJ (gastro-oesophageal junction)
1440.1 - PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer
1527 - Somatic tumour gene testing for the diagnosis of gliomas, gliobastomas, and soft tissue and bone tumours
1528 - Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast
1512 - Apolipoprotein B testing for high risk cardiovascular disease risk assessment
1526 - Somatic tumour gene testing for the diagnosis of diffuse large B cell lymphoma, multiple myeloma and non-Hodgkin lymphoma subtypes
1525 - Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer
1495 - Somatic tumour gene panel test
1180r - Review of items for surgical treatment of obesity
1519 - Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive leukaemia and lymphoma
1479r - Substitution of 68Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369
1357.1 - F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer
1482 - New item numbers and rebates for mobile radiology services
1505 - Programmed cell death ligand 1 (PD L1) testing in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) to determine eligibility for durvalumab monotherapy or durvalumab/tremelimumab combination therapy (co dependent).
1511 - Extended half-life (EHL) blood clotting factors VIII + IX
1498 - Serum soluble transferrin receptor
1506 - Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with unresectable Stage IV urothelial cancer
1510 - Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with Haemophilia A (congenital Factor VIII deficiency) with Factor VIII inhibitors.
1508 - Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Solid tumours other than colorectal cancer
1507 - Germline BRCA mutation testing to determine eligibility for olaparib treatment in patients with locally advanced or metastatic HER2 negative breast cancer (either hormone receptor positive or triple negative)
1509 - Annular Closure using the Barricaid® mesh prosthesis after discectomy
1342.4 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)
1456 – 17p Deletion Testing for Access to Venetoclax in Patients with Relapsed/Refractory Chronic Lymphoid Leukaemia
1490 - Breast Magnetic Resonance Imaging for Breast Implant Associated Anaplastic Large Cell Lymphoma
1491 – Vagus nerve stimulation for chronic major depressive episodes
1216.1 - Cystic fibrosis transmembrane regulator (CFTR) testing
1493 - Transarterial radioembolisation with yttrium-90 (TARE-Y) for the treatment of unresectable hepatocellular carcinoma
1472– Cyanoacrylate embolisation for the treatment of varicose veins due to chronic venous insufficiency
1485 – Sentinel Lymph Node Biopsy for intermediate thickness melanoma
1496 Micro-bypass stenting for open-angle glaucoma (external to Schlemm's canal)
1376.1 - 70 gene signature (MammaPrint) for use in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit
1476 - Genetic testing for childhood syndromes
1464 - Breast Magnetic Resonance Imaging for improved definition of the breast cancer primary
1473 - A 50 gene signature assay for predicting breast cancer recurrence
1468 - SIR-Spheres for the treatment of hepatic metastases, and other indications not listed on the MBS
1483 Micro-bypass stenting for open-angle glaucoma (in trabecular meshwork)
1146.3 - Capsule Endoscopy for the Diagnosis of Suspected Small Bowel Crohn Disease (Resubmission)
1455 - Proton Beam Therapy for patients supported under the Medical Treatment Overseas Program
1467 - Obstetric MRI
1372.1 MRI for patients with colorectal carcinoma (CRC) with suspected hepatic metastases or patients with suspected hepatocellular carcinoma (HCC) for the purposes of staging
1196.1 - Repetitive Trans cranial Magnetic Stimulation (rTMS) for the treatment of depression (resubmission)
1466 - Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration
1475 - Ablative fractional laser resurfacing for burn scar treatment
1460 - Blue-light cystoscopy with hexaminolevulinate as an adjunct to standard white light cystoscopy, for the diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC)
1454 - Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment
1457 PD-L1 (Programmed Death 1 Ligand) IHC (immunohistochemistry) testing for access to pembrolizumab as first-line therapy for patients with unresectable or metastatic bladder cancer ineligible for cisplatin-based therapy.
1449 Genetic testing for Alport syndrome
1461 Non-invasive prenatal testing for common trisomies (21, 18 and 13)
1458 Non-Invasive Prenatal Testing (NIPT)
1453 PD-L1 testing for access to pembrolizumab in patients with unresectable mesothelioma
1452 Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma
1398.1 - Implantation of a permanent wireless haemodynamic sensor and associated remote analysis of pulmonary artery pressure for patients with moderate chronic heart failure (New York Heart Association class III)
1362.1 - Resubmission Cetuximab and RAS testing under MBS 73330
1411.1 - Genetic testing for hereditary mutations predisposing to cancer (breast and/or ovarian) (resubmission)
1151 - Six Genetic tests for the Diagnosis of Inheritable Cardiac Conduction Disorders
1436 - Ovarian Repositioning
1165.1 - Pre-implantation genetic diagnosis (PGD) assessment
1406 - 18F-FDG PET for indolent non-Hodgkin’s lymphoma
1347.1 - Transcatheter occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation (resubmission)
1358.1 - Vagus Nerve Stimulation Therapy (resubmission)
1387.1 - OPTIMIZER TM IVs Implantable Pulse Generator (IPG) – cardiac contractility modulation therapy for patients with heart failure (resubmission)
1435 - Processing and Cryopreservation of Male and Female Gonadal Tissue and Gametes Prior to or after Gonadotoxic Treatment to Preserve Fertility for the Future
1420 - Extracorporeal photopheresis for treatment of acute and chronic graft-versus-host disease and cutaneous T-cell lymphoma
1432 - Magnetic resonance imaging of patients with suspected non-ischaemic cardiomyopathies
1384.1 - Bronchial thermoplasty for the treatment of severe persistent asthma (Resubmission)
1440 - PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer
1445 - PD-L1 testing for access to pembrolizumab in patients with recurrent or progressive metastatic bladder cancer that has recurred or progressed following platinum-based chemotherapy
1431 - HbA1c point of care test for the diagnosis and management of diabetes mellitus
1443 - Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke
1439 - Intravesical instillation of sodium hyaluronate (1.6%) & sodium chondroitin sulphate (2.0%) for Painful Bladder Syndrome / Interstitial Cystitis, Recurrent Urinary Tract Infection and Radiation Induced Cystitis
1342.3 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)
1192.2 - Reduction of mitral regurgitation through tissue approximation, using transvenous/transeptal techniques (Resubmission)
1411 - Genetic testing for hereditary mutations predisposing to cancer (breast and/or ovarian)
1172.1 - Testing for BRAF mutation in patients with metastatic melanoma for access to vemurafenib (resubmission)
1361.2 - Transcatheter Aortic Valve Implantation via Transfemoral or Transapical Delivery (Resubmission)
1422 - Minimally invasive, lumbar decompression and dynamic stabilisation using an interlaminar device, with no rigid fixation to the vertebral pedicles, implantation between the spinous processes of one or two lumbar motion segments
1434 - Anti-Müllerian hormone testing
1429 - Intraoperative Radiotherapy for Early Stage Breast Cancer
1428 - Mechanical thrombectomy
1344.1 - Assessment of foot and ankle services by podiatric surgeons (Resubmission)
1365.1 - Active middle ear implants for sensorineural hearing loss (Resubmission)
1342.2 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)
1424 - MR guided biopsy procedures for diagnosis of prostate cancer
1414 - PD-L1 testing for access to Pembrolizumab for the treatment of locally advanced or metastatic NSCLC
1163.1 - Testing for HER2 status in Gastric Cancer for access to trastuzumab
1331 - Review of archival tissue for further diagnostic testing
1400 - Clinical Neuropsychology Assessment Services
1360.1 - Specialist dermatology services delivered by asynchronous store and forward technology (resubmission)
1408 - A prognostic RT-qPCR test run locally for ER+ve /HER2-ve breast cancer that determines the risk of early and late metastasis in node negative and positive cancer under endocrine treatment.
1407 - EGFR mutation testing to determine eligibility for access to PBS subsidised AZD9291 second line therapy in patients with locally advanced or metastatic NSCLC
1405 - MBS Item Number for Pulmonary Rehabilitation
1403 - Lung Microwave Tissue Ablation
1402 - Liver Microwave Tissue Ablation
1397 - mpMRI prostate diagnostic scans
1399 - Percutaneous Tibial Nerve Stimulation administered through the Urgent PC Neuromodulation
1401 - Endobronchial Coil Procedure
1393-Magnetic resonance imaging of patients with suspected non-ischaemic cardiomyopathies
1395 - Fluorescence guided resection of high grade (grade IV) glioma that are glioblastoma multiforme using Gliolan (aminolevulinic acid)
1392 - Corneal Collagen Cross Linking as early intervention in progressive keratoconus
1385 - Shared Medical Appointments (SMAs) for Type 2 Diabetes Management
1398 - Implantation of a permanent leadless and batteryless haemodynamic sensor and associated remote analysis of pulmonary artery pressure for patients with moderate chronic heart failure (New York Heart Association class III).
1366 - Transient Elastography at 50Hz for the diagnosis of Liver Fibrosis in patients with confirmed Hepatitis B or confirmed Hepatitis C
1394 - C1 Esterase Inhibitor
1250.1 - Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)
1197.1 - Remote Monitoring of Patients with Implanted Cardiac Devices
1396 - Noninvasive prenatal testing for common trisomies (21, 18 and 13)
1390 - Epicutaneous Patch Testing
1369 - Male stress urinary incontinence, sling operation for, with or without synthetic mesh
1384 - Bronchial thermoplasty for the treatment of severe persistent asthma
1387 - Cardiac Contractility Modulation (OPTIMIZER™ IVs)
1386 - Gastric Contractility Modulation (GCM) therapy for patients with Type 2 Diabetes with Obesity (DIAMOND™ system Funding Application)
1391 - Rapid point of care combined Antigen/Antibody HIV test to aid in the diagnosis of HIV infection
1379 - IncobotulinumtoxinA (XEOMIN), injection of, for blepharospasm, cervical dystonia (spasmodic torticollis) and post-stroke spasticity of the upper limb
1361 and 1361.1 - Transcatheter Aortic Valve Implantation via Transfemoral or Transapical Delivery
1380 - BRCA mutation testing to determine eligibility for olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
1356 - Melanoma surveillance photography – total body photography and digital dermoscopy
1189 - Targeted intraoperative radiotherapy (IORT) for early breast cancer
1377 - Optical coherence tomography (OCT) for retinal assessment in the presence of diabetic macular oedema (DMO) for access to treatment with dexamethasone posterior segment drug delivery system
1342.1 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)
1351 - Point of care tests to exclude pre-term labour:Quantitative Fetal Fibronectin (fFN) testing for predicting pre-term labour
1376 - MammaPrint® 70-gene microarray mRNA gene expression profile breast cancer signature to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit.
1372 - MRI Liver – Scan for the detection and characterisation of focal liver lesions
1192.1 - The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques (resubmission)
1234 - Pathology tests for active mycobacterial infection
1367 - Gastrointestinal liner ['EndoBarrier'] to treat diabetes and obesity
1365 - Active middle ear implants for sensorineural hearing loss
1364 - Active middle ear implant for mixed and conductive hearing loss
1345 - Cone Beam CT for dental/craniofacial imaging
1158.1 - Robotic Image-guided stereotactic precise beam radiosurgery and radiotherapy for lung (Cyberknife) - resubmission
1354 - Intravascular ultrasound (IVUS) guided coronary stent insertion
1374 - Insertion of subcutaneous electrode for the purpose of use with an implantable cardioverter defibrillator (ICD)
1370 - Ocriplasmin for symptomatic vitreomacular adhesion (sVMA) including macular hole
1363 - RAS (Kirsten RAS and Neuroblastoma RAS) mutation testing for eligibility for panitumumab treatment in previously untreated metastatic colorectal cancer patients
1362 - Cetuximab and KRAS testing under MBS 73330
1358 - Vagus Nerve Stimulation Therapy
1335 - Point of Care Tests to exclude preterm labour: Phosphorylated Insulin-like Growth Factor Binding Protein test
1216 - Cystic fibrosis transmembrane regulator (CFTR) testing
1355 - Review of Medicare funded finger fracture services
1237 - Cardiovascular MRI
1359 - Perioperative Nurse Surgical Assistants (PNSA) to gain eligibility as providers of services that attract a Medicare Benefit Schedule (MBS) rebate for eligible surgical assisting services provided during surgery or procedures.
1350 - Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)
1346 - Amendment to MBS Item 11820
1348 - Transcatheter closure of ventricular septal defect
1357 - F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer
1360 - Specialist dermatology services delivered by asynchronous store and forward technology
1169 - Sports and Exercise medicine consultation Items
1338 - Catheter-based renal denervation for treatment-resistant hypertension
1353 - Measurement of Calprotectin as a marker of bowel inflammation
1165 - Pre-implantation genetic diagnosis (PGD) assessment
1347 - Transcatheter occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation
1318 - KRAS mutation testing for access to panitumumab
1205a - Review of Medicare–funded Wrist Surgery services
1344 - Assessment of foot and ankle services by podiatric surgeons
1146.1 - Capsule Endoscopy for the Diagnosis of Suspected Small Bowel Crohn Disease (Resubmission)
1333 - Breast Magnetic Resonance Imaging (MRI)
1332 - Second Opinion for Morphological/Interpretive Pathology
1309 - Pain Medicine Professional Attendance Items
1308 - Local anaesthetic (LA) nerve blockade for post-surgical analgesia
1233 - Out of hours emergency coronary angiography and/or coronary angioplasty and stenting
1181 - Non-mydriatic retinal photography (NMP) in persons with diabetes
1334 - Subcutaneous Immunoglobulins (SCIg)
1342 - Gene expression profiling of 21 genes in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit
1330 - Transcatheter closure of a patent ductus arteriosus
1319 - The use of Image Guided Radiation Therapy (IGRT) in the treatment of cancer
1293 - Codependent with PBAC- EGFR testing in Patients with Locally Advanced or Metastatic Non Small-Cell Lung Cancer to determine eligibility for afatinib
1317 - Bone Mineral Density using Dual Energy X-Ray Absorptiometry (DXA) in patients with HIV
1176 - Assessment of application for Joint Injections
1300 - Removal of gynaecomastia from the liposuction component in Barraquers-Simon’s Syndrome (MBS Item 45585)
1299 - Proposed amendment to transperineal ultrasound prostate biopsy (MBS Item 37219)
1230 - Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab
1313 - Bone mineral density analyses using Dual Energy X-Ray Absorptiometry (DXA) in breast cancer patients receiving aromatase inhibitor treatment
1316 - Bone mineral density analyses using Dual Energy X-Ray Absorptiometry (DXA) for persons aged 50 - 69 with specific risk factors
1243 - The removal of imbedded corneal foreign bodies to any person presenting to an optometrist.
1191 - Endovascular treatment of intracranial aneurysms-Pipeline Embolization Device (PED)
1263 - Intra-abdominal Vagal Nerve Inhibition for the Management of Obesity
1310 - Optical Coherence Tomography
1269 - Computed Tomography Colonography
1248 - Bone Densitometry to Assess Patient Eligibility to alendronate
1272 - Transurethral Injection of Botulinum Toxin (Botox) into the Bladder Wall for Urinary Incontinence due to Idiopathic Overactive Bladder
1162 - Bone Densitometry testing for menopausal women aged 50
1223 - Insertion, replacement, or removal of a cardiac resynchronisation therapy device capable of defibrillation (CRT-D) for mild, moderate or severe chronic heart failure (NYHA II, III or IV)
1297 - HBA1c test for the diagnosis of diabetes mellitus
1197 - Remote Monitoring of Patients with Implanted Cardiac Devices
1196 - Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression.
1267 - HBA1c Test for the Diagnosis of Diabetes Mellitus
1206 - Single Balloon Enteroscopy System for Obscure GI Bleeding (Small Bowel)
1194 - Single dose stereotactic radiosurgery for benign and malignant intracranial tumours
1183 - Ultrasound imaging in the practice of anaesthesia.
1182 - The use of Intensity Modulated Radiation Therapy (IMRT)
1159 - Palliative Care consultation Items
1203 - Catheter-free ambulatory pH test for gastroesophageal reflux disease (GORD)
1170 - Intensive Care Medicine consultation Items
1171 - Sexual Health Medicine consultation Items
1167 - Addiction medicine consultation Items
1195 - F-18 Flurodeoxyglucose Positron Emission Tomography (FDG PET) for the diagnosis of Alzheimer's Disease
1268 - Radium 223 for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases
1250 - Testing of the ALK gene in tumour material from patients with non-small cell lung cancer to determine eligibility for treatment with crizotinib
1273 - Matrix-induced Autologous Chondrocyte Implant
1222 - A genetic test to establish the diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) for access to tafamidis meglumine
1211 - Volumetric Modulated Arc Therapy for Lung, Prostate, breast and other extracranial cancers such as spine, kidney, liver and pancreatic.
1276 - National Cervical Screening Program renewal
1190 - MRI for small bowel and pelvis in Crohn disease
1242 - yttrium-90 microsphere radioembolisation to embolise the microvasculature of hepatic primary and secondary cancers
1175 - Testing for HER-2 status in Advanced or Metastatic Breast Cancer (stage IIIA-IV) to Access lapatinib
1192 - Percutaneous Reconstruction of an Insufficient Mitral Valve through Tissue Approximation using Transvenous/ Transeptal Techniques
1221 - Transurethral Injection of Botulinum Toxin into the Bladder Wall for Urinary Incontinence due to Neurogenic Detrusor Overactivity
1207 - Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies
1178r2 - Review of MBS items for specific ophthalmology services under the MBS Quality Framework Stage II
1152 - Genetic testing for hereditary mutations in the RET gene
1168 - Injection of Botulinum Toxin (Botox) for Prophylaxis of Headaches in Adults with Chronic Migraine
1172 - Testing for BRAF mutation in patients with advanced melanoma for access to vemurafenib
1166 - Radiofrequency ablation (RFA) for the treatment of varicose veins due to chronic venous insufficiency
1174 - Pathology test to determine if a patient has been infected with CCR5 tropic HIV-1 for access to maraviroc
1173 - Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) for access to erlotinib
1158 - Robotic image-guided stereotactic precise beam radiosurgery and radiotherapy
1098.1 - Review of Interim Funded Service: Breast MRI
1161 - Gefitinib first line testing for mutations of epidermal growth factor receptor (EGFR) in patients with metastatic non-small cell lung cancer
1157 - Cell enrichment liquid based cytology in routine screening for the prevention of cervical cancer
1163 - Testing for gastric cancer for access to trastuzumab
1160 - Hepatitis C testing for access to Telaprevir
1154 - Patient Monitor Module for non-invasive assessment of artificial stiffness and titration of anti-hypertensive medication in Chronic Kidney Disease
1156 - Diagnostic use of thyrotropin alfa-rch for Patients with Well-Differentiated Thyroid Cancer
1153 - Genetic Testing for Hereditary Mutation of the von Hippel-Lindau (VHL) Gene
1150 - Insertion of Colonic Stents
1149 - Holmium Laser Enucleation of the Prostate (HOLEP) Combined with Tissue Morcellation
1145 - Artificial Intervertebral Disc Replacement in Patients with Cervical Degenerative Disc Disease
1147 - Implantation of fiducial markers into the prostate gland or prostate surgical bed for external beam radiotherapy
1146 - Capsule Endoscopy for the Diagnosis of Suspected Small Bowel Crohn's Disease
1054.1 - Review of Interim Funded Service: Hyperbaric Oxygen Treatment (HBOT)
1143 - Radiofrequency Ablation in Barrett's Oesophagus with Dysplasia
1144 - Pathology Tests for Latent Mycobacterial Infection
1089.1 - Review of Interim Funded Service: Brachytherapy for the Treatment of Prostate Cancer
1090.1 - Review of Interim Funded Service: Artificial Intervertebral Disc Replacement - Lumbar
1140 - Matrix-induced Autologous Chondrocyte Implantation (MACI) and Autologous Chondrocyte Implantation (ACI)
1134 - The Injection of Poly-L-lactic Acid (Sculptra) for the Treatment of Facial Lipoatrophy Caused by Antiretroviral Therapy in HIV Positive Patients
1139 - Measurement and Determination of Procalcitonin (PCT)
1137 - Middle Ear Implant for Sensorineural, Conductive and Mixed Hearing Losses
1110 - MRI for staging of rectal carcinoma
1130 - Unattended Sleep Studies in the Diagnosis of Obstructive Sleep Apnoea
1129 - Second Generation Contrast Agents for Use in Patients with Suboptimal Echocardiograms
1131 - Assessment of Liver Iron by R2-MRI data analysis
1125 - Molecular Testing for the Diagnosis of Myeloproliferative Disorders
1126 - Molecular Testing for Developmental Delay/Mental Retardation
1119 - Capsule Endoscopy for Peutz - Jeghers Syndrome
1127 - Genotypic Resistance Testing of Antiretrovirals in HIV
1124 - Cryotherapy for Recurrent Prostate Cancer and Renal Cancer
1123 - Computer-Navigated Total Knee Arthroplasty (CATKA)
1122 - Automation-Assisted and Liquid-Based Cytology (LBC) for Cervical Cancer Screening
1118 - Vagus nerve stimulation
1116 - Macular Optical Coherence Tomography
1117 - Real-time measurement of cardiac output and other cardiac flow parameters (without concurrent cardiac imaging) using continuous wave Doppler techniques
1111 - Remote Monitoring Systems for Patients with Implanted Cardiac Device
1114 - Urinary metabolic profile
1109 - Deep brain stimulation for essential tremor and dystonia
1113 - Endovenous Laser Therapy for varicose veins (ELT)
1112 - Intragastric Balloon
1108 - Endobronchial ultrasound +/- fine needle aspiration in lung cancer staging and the diagnosis of mediastinal masses
1107 - Acticon artificial bowel sphincter
1024 - Total ear reconstruction
1046 - Sacral nerve stimulation implant (SNSI) for refractory lower urinary tract dysfunction of the following types: urge incontinence, urgency-frequency and retention/overflow
1089 - Brachytherapy for the treatment of prostate cancer
1076 - High-energy transurethral microwave thermotherapy for benign prostatic hyperplasia
1056 - Leukoscan®: For use in diagnostic imaging of the long bones and feet in patients with suspected osteomyelitis, including those with diabetic foot ulcers
1054 - Hyperbaric oxygen therapy for the treatment of non-healing, refractory wounds in non-diabetic patients and refractory soft tissue radiation injuries
1053 - Placement of artificial bowel sphincters in the management of faecal incontinence
1062 - CEA-Scan® for imaging of recurrence &/or metastases in patients with histologically demonstrated carcinoma of the colon or rectum
1049 - M-VAX™ - a treatment for patients with advanced Stage III melanoma
1045 - Intra-articular viscosupplementation for treatment of osteoarthritis of the knee
1044 - Ostase immunoassay for the mass measurement of serum bone alkaline phosphatase
1048 - Intradiscal electrothermal anuloplasty: A treatment for patients with chronic low back pain due to anular disruption of contained herniated discs
1047 - Endoluminal gastroplication for gastro-oesophageal reflux disease
1014 - Transurethral needle ablation (TUNA) for the treatment of benign prostatic hyperplasia
1041 - Intravascular Brachytherapy for Coronary Artery Restenoses
1015 - Directional vacuum-assisted breast biopsy
1043 - Recombinant human thyroid stimulation hormone (rhTSH) diagnostic agent for use in well-differentiated thryoid cancer
1039 - Photodynamic therapy with Verteporfin for macular degeneration
1036 - Percutaneous transluminal coronary rotational atherectomy for lesions of the coronary arteries
1038 - Conformal radiotherapy
1037 - Advanced breast biopsy instrumentation (ABBI®) system for non-palpable breast lesions
1035 - Genetic test for Fragile X syndrome
1031 - Deep brain stimulation for the symptoms of Parkinson's disease
1029 - Brachytherapy for the treatment of prostate cancer
1026 - Evaluation of near patient cholesterol testing using the Cholestech LDX
1021 - Hepatitis C viral load testing
1018 - 1020 - Hyperbaric oxygen therapy (HBOT)
1016 - Samarium153-lexidronam for pain due to skeletal metastases
1034 - Selective internal radiation therapy (SIRT) for hepatic metastases using SIR-Spheres®
1032 - Intravascular ultrasound
1028 - Gamma knife radiosurgery
1030 - Low intensity ultrasound treatment for acceleration of bone fracture healing - Exogen™ bone growth stimulator
1023 - Placement of artificial bowel sphincters in the management of faecal incontinence
1106 - Endoscopic argon plasma coagulation therapy
1010 - Intravascular extraction of chronically implanted permanent transvenous pacing leads
1007 - Saline infusion sonohysterography
1005 - Visual electrodiagnosis
1003 - OctreoScan® scintigraphy for gastroentero-pancreatic neuroendocrine tumours
1002 - Oto-acoustic emission audiometry
1012 - Vertebral axial decompression therapy for chronic low back pain
1011 - Lung volume reduction surgery
1008 - Photodynamic therapy for skin and mucosal cancer
1006 - Endoluminal grafting for abdominal aortic aneurysm
1004 - Transmyocardial laser revascularisation (TMR)
1001 - Advanced breast biopsy instrumentation (ABBI)
1009 - Sacral nerve stimulation for refractory urinary urge incontinence or urinary retention
1077 - Sacral nerve stimulation for faecal incontinence
1042 - Cardiac resynchronisation therapy (CRT)
1071 - The use of INR point-of-care testing in general practice
1068 - Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer
1115 - Sacral Nerve Stimulation for Urinary Indications
1055 - Hysteroscopic Sterilisation by Tubal Canulation and Placement of Intrafallopian Implant
1050 - Optical Biometry using partial coherence interferometry prior to cataract surgery
1059 - Endo Venous Laser Treatment for Varicose Veins
1057 - M2A® Capsule Endoscopy: For the evaluation of obscure gastronintestinal bleeding in adult patients
1052 - Radiofrequency ablation of liver tumours
1102 - Double Balloon Enteroscopy
1105 - Computed Tomography Coronary Angiogram - Multi-slice computed tomography coronary angiography in the visualisation of coronary arteries
1104 - Endoscopic ultrasound and fine needle aspiration for lung cancer
1103 - Fetal Fibronectin test for Preterm Labour
1082 - SIR-Spheres ® for the treatment of non-resectable liver tumours
1083 - Intac Implants
1101 - Repetitive Transcranial Magnetic Stimulation (rTMS)
1100 - Intersphinteric Injection of Silicone Biomaterial for Severe Passive Faecal Incontinence
1099 - Lumbar Non-fusion Posterior Stabilisation Devices
1098 - Breast magnetic resonance imaging (MRI)
1096 - Hepatitis B DNA testing
1095 - Computed tomography colonography
1093 - Endovascular Neurointerventional Procedures
1092 - Deep brain stimulation for the symptoms of Parkinson's disease
1091 - Laparoscopic remotely assisted radical prostatectomy
1084 - Uro Vysion Fluorescence Insitu Hybridization (FISH) Assay
1078 - Multifocal multi-channel objective perimetry for the diagnosis of visual field defects
1067 - Genotypic resistance testing of antiretrovirals in HIV
1090 - Artificial Intervertebral Disc Replacement (AIDR)
1061 - Implantable Loop Recorder for Unexplained Syncope - Reveal Plus®
1072 - Endoscopic ultrasound for staging pancreatic, gastric, oesophageal and hepato-biliary neoplasms
1065 - Sentinel lymph node biopsy
1063 - Photodynamic therapy for Verteporfin (Visudyne) for Subfoveal choroidal neovascularisations (Commercial in Confidence)
1060 - Bone Mineral Densitometry
1033 - Autologous chondrocyte implantation (ACI)
1085 - Carbon Labelled Urea Breath Test
1081 - Uterine Artery Embolisation (UAE) 1
1080 - Coronary (Radi) pressure wire
1079 - Peripheral Arterial Tonometry with Ascending Aortic Waveform Analysis using the SphygmoCor System
1086 - Measurement of B-Type Natriuretic Peptide
1087 - Brain natriuretic peptide assays in the diagnosis and monitoring of heart failure